Background: The once-in-a-lifetime recommendation for vaccination against yellow fever virus (YFV) has been controversial, leading to increased scrutiny of the durability of immunity after 17D vaccination.
Methods: This is a cross-sectional analysis of 17D vaccinees living in nonendemic Portland, Oregon. Neutralization assays were used to determine YFV immunity. The relationships between 17D immunity and vaccination history, demographics, and travel were evaluated using nominal logistic regression.
Results: Seventy-one of 92 (77.2%) subjects were YFV seropositive (90 percent plaque reduction neutralization test ≥1:10) at all timepoints, and 24 of 38 (63.8%) were YFV seropositive at ≥10 years after single-dose vaccination. No relationship was found between YFV immunity and time in endemic countries, other flavivirus immunity, or demographics. Subjects were most likely to become seronegative between 3 and 12 years postvaccination (logistic regression, odds ratio [OR] = 1.75; 95% confidence interval [CI], 1.12-2.73). A comparison of our results and 4 previous studies of YFV nonendemic vaccinees found that overall, 79% (95% CI, 70%-86%) of vaccinees are likely to be seropositive ≥10 years postvaccination.
Conclusions: These results suggest that 1 in 5 17D vaccinees will lack neutralizing antibodies at ~10 years postvaccination, and a booster vaccination should be considered for nonendemic vaccinees before travel to regions where there is a high risk of YFV transmission.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289542 | PMC |
| http://dx.doi.org/10.1093/infdis/jiz374 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of anti-premembrane antibody as a specific marker of four flavivirus serocomplexes and its application to serosurveillance in endemic regions.
Emerg Microbes Infect
December 2024
Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.
Article Synopsis
- * The study developed a serological assay using anti-premembrane (prM) antibodies to distinguish between infections from four major flavivirus serocomplexes: dengue, Zika, West Nile, and yellow fever.
- * Results showed high sensitivity and specificity for identifying infections in various samples from Brazil and the Philippines, suggesting that anti-prM antibodies can effectively differentiate flavivirus exposures in co-circulating environments.
Article Synopsis
- Emerging mosquito-borne flaviviruses like dengue, Zika, West Nile, and yellow fever are causing public health issues, complicating serosurveillance due to overlapping antibody responses.
- This study developed a serological assay utilizing anti-premembrane (prM) antibodies, which effectively discriminated between infections of the four flavivirus serocomplexes, showing high sensitivity and specificity.
- The assay was tested on serum samples from Brazil and the Philippines, revealing various co-infections and confirming the utility of prM antibodies for identifying flavivirus infections in endemic regions.
Absence of transmission of vYF next generation Yellow Fever vaccine in mosquitoes.
PLoS Negl Trop Dis
December 2022
Institut Pasteur, Université Paris Cité, Arboviruses and Insect Vectors, Paris, France.
One of the most effective vaccines against an arbovirus is the YFV-17D live-attenuated vaccine developed in 1937 against Yellow Fever (YF). This vaccine replicates poorly in mosquitoes and consequently, is not transmitted by vectors. Vaccine shortages, mainly due to constrained productions based on pathogen-free embryonated eggs, led Sanofi to move towards alternative methods based on a state-of-the-art process using continuous cell line cultures in bioreactor.
View Article and Find Full Text PDFFluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D.
PLoS One
February 2022
Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
There is an urgent need for better diagnostic and analytical methods for vaccine research and infection control in virology. This has been highlighted by recently emerging viral epidemics and pandemics (Zika, SARS-CoV-2), and recurring viral outbreaks like the yellow fever outbreaks in Angola and the Democratic Republic of Congo (2016) and in Brazil (2016-2018). Current assays to determine neutralising activity against viral infections in sera are costly in time and equipment and suffer from high variability.
View Article and Find Full Text PDFGenotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies.
Cell Host Microbe
February 2022
Department of Microbiology and Immunology, Albert Einstein College of Medicine, The Bronx, NY 10461, USA. Electronic address:
The resurgence of yellow fever in South America has prompted vaccination against the etiologic agent, yellow fever virus (YFV). Current vaccines are based on a live-attenuated YF-17D virus derived from a virulent African isolate. The capacity of these vaccines to induce neutralizing antibodies against the vaccine strain is used as a surrogate for protection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!